GHK-CU 50mg

GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a tripeptide-metal complex where the peptide GHK (MW: 340 Da free form) chelates a cupric ion (Cu²⁺), forming a stable blue-violet complex (MW: 402 Da). Originally discovered in human serum, plasma, and saliva, GHK-Cu decreases with age (from ~200 ng/mL at 20 years old to ~80 ng/mL at 60 years old), correlating with regenerative decline.

Molecular Structure and Chelation

• Gly-His-Lys
• Copper(II) ion: square planar coordination
• Chelating sites: imidazole nitrogen (His), N-terminal amino group (Gly), carboxyl oxygen
• Constant stability: log K = 16.4 (high affinity Cu²⁺)
• Characteristic color: blue-purple (d-d transition Cu²⁺)

Pleiotropic Molecular Mechanisms:

1. Extracellular Matrix Remodeling

• Collagen/Elastin Synthesis
  • Upregulation of type I collagen: +70% in dermal fibroblasts
  • Type III collagen: +50%
  • Elastin: increase of 80% (improves skin elasticity)
  • Decorin, lumican: proteoglycan modulation
• MMP/TIMP Regulation:
  • MMP-1 (collagenase): 75% reduction (prevention of collagen degradation)
  • MMP-2: gelatinase activity modulation
  • TIMP-1/2: increased inhibitors (remodeling balance)

2. Potent Antioxidant Activity:

• Ferrous iron (Fe²⁺) chelation: prevention of Fenton reactions
• Superoxide radical scavenging: increased ORAC capacity
• Lipoperoxidation protection: MDA (malondialdehyde) reduction 60%
• Endogenous antioxidant regeneration: glutathione, catalase

3. Extensive Gene Modulation

• Microarray analysis: modulates >4000 genes (Pickart et al., 2012)
• Upregulated Genes: DNA repair, anti-inflammatories, antioxidants
• Downregulated Genes pro-inflammatory, fibrotic, apoptotic
• Gene expression reset: reversion of aging patterns

4. Growth Factors and Cytokines

• VEGF: increase of 60–80% (angiogenesis)
• TGF-β: modulation of the profibrotic/reparative balance
• IL-6: 50% reduction (anti-inflammatory)
• TNF-α: decrease 40%

5. Stem Cell Differentiation:

• Mesenchymal stem cells: osteogenic lineage promotion
• Follicular stem cells: dermal papilla cell differentiation
• Neural Stem Cells: Support Neuronal Differentiation

Pharmacokinetics (Topical/Systemic):

• Skin absorption: 10–15% (formulation-dependent)
• Dermal penetration: reaches the reticular dermis
• SC Bioavailability: 70–80%
• Serum half-life: 1-2 hours
• Distribution: widespread, accumulation in injured tissues

1. SKIN REGENERATION AND ANTI-AGING

Facial Rejuvenation

Human Clinical Studies

• Wrinkle depth: reduction of 35–40% after 12 weeks (Pickart & Margolina, 2018)
• Skin elasticity: improvement of 25–30% (cutometry)
• Collagen density: increase 18% (high-frequency ultrasound)
• Epidermal thickness: increase 15%
• Skin texture: improves softness, radiance (image analysis)

Underlying Mechanisms:

• Fibroblast activation: increased synthesis of new collagen
• MMP-1 inhibition: protection of existing matrix
• Procollagen I Stimulation: Efficient Conversion to Mature Collagen
• Improved elastic net: dermal elastic fiber restoration

UV Protection and Photoaging:

• UV-induced damage: reduction in thymine dimer formation (50%)
• UV immunosuppression: prevention of Langerhans cell depletion
• Solar elastosis: partial reversion of abnormal elastic fibers
• Hyperpigmentation: tyrosinase regulation, reduction of dark spots 30%

Wound Healing:

• Wound Healing: Acceleration 40% (ex vivo human skin models)
• Re-epithelialization: keratinocyte migration +150%
• Angiogenesis: vascular density +200% in granulation tissue
• Scar quality: hypertrophic scar reduction, collagen orientation improvement

2. HAIR GROWTH AND REGENERATION

Follicle Stimulation

• Follicle enlargement: increase in follicle size 30%
• Anagen transition: prolongation of the growth phase 25%
• Hair thickness: increase in shaft diameter 12-15%
• Hair density: improved by 10–15% after 6 months

Follicular Mechanisms

• Dermal papilla cells: Wnt/β-catenin signaling activation
• Growth factor: upregulation of VEGF, IGF-1, KGF in the follicle
• Keratinocyte matrix: increased proliferation
• Melanogenesis: Support for follicular melanocytes

Androgenetic Alopecia

• DHT antagonism: modulation of follicular androgen receptors
• Perifollicular inflammation: reduction of inflammatory infiltrate
• Vascularization: improves capillary bulb perfusion

3. ANTI-INFLAMMATORY AND HEALING EFFECTS

Inflammatory Response Modulation

• NF-κB: inhibition of nuclear translocation 55%
• Pro-inflammatory cytokines: IL-1β (-50%), IL-6 (-50%), TNF-α (-40%)
• Lipid mediators: prostaglandin, leukotriene modulation
• Leukocyte infiltration: reduction in neutrophils/macrophages in tissue

Burns and Skin Trauma

• Second-degree burns: reduced re-epithelialization time 35%
• Scar formation: reduction of tissue necrosis
• Infection: Moderate antimicrobial properties (Cu²⁺ synergy)
• Pain: reduced nociceptor sensitization

4. DEEP TISSUE PROTECTION AND REPAIR

Cardiovascular System:

• Cardiac fibrosis: reduced collagen deposition after MI 40%
• Ventricular remodeling: preservation of LV geometry
• Myocardial angiogenesis: collateralization improvement
• Endothelial dysfunction: NO production restoration

Lung

• Pulmonary fibrosis: bleomycin-induced attenuation 50%
• EMT (epithelial-mesenchymal transition): TGF-β-mediated inhibition
• Functional capacity: lung volume preservation
• Inflammation: reduction of eosinophilic/neutrophilic infiltrates

Kidney

• Diabetic nephropathy: reduction in proteinuria 45%
• Interstitial fibrosis: decreased renal collagen
• Podocytes: protection loss, preservation filtration
• Kidney function: improving creatinine, BUN

5. NEUROPROTECTION AND NEURAL REPAIR

Neurogenic Effects

• Neural differentiation: stem cell promotion → neurons
• Neurite formation: increased neurite elongation 80%
• Synaptogenesis: improves synaptic density 40%
• BDNF: neurotrophic factor upregulation

Neurodegenerative Models

• Alzheimer's: Reduction in β-amyloid 35% Improves Cognition
• Parkinson's Disease: Protection of Dopaminergic Neurons 45%
• ALS: Slowing Progression in Mouse Models
• Cerebral ischemia: reduction in infarct size 30%

Peripheral Nerve Repair

• Axonal regeneration: acceleration of elongation 60%
• Remyelination: Schwann cell promotion
• Functional recovery: improved nerve function index

Dosage Preclinical Research

Topical Applications

Systemic Applications

Specialized In Vitro Studies

Human Dermal Fibroblasts:

• Concentration: 0.1–10 μM (typically 1 μM optimal)
• Collagen Synthesis: Sircol Assay, Western Blot COL1A1
• MMPs/TIMPs: gelatin zymography, ELISA
• Proliferation: MTT, BrdU incorporation
• Migration: scratch assay, Boyden chamber

Keratinocytes (HaCaT):

• Concentration: 0.5-5 μM
• Differentiation: involucrin, filagrin expression
• Barrier: transepithelial electrical resistance (TEER)
• Reepithelialization: wound healing assay

Endothelial Cells (HUVEC):

• Angiogenesis: 0.5-2 μM in Matrigel
• Tubulogenesis: capillary network quantification
• Migration: Transwell + GHK-Cu gradient
• VEGF secretion: ELISA

Neural Crops

• Primary neurons: 0.1-1 μM
• Neurogenesis: βIII-tubulin, neurite length
• Differentiation: MAP2, NeuN markers
• Viability: Calcein-AM, PI exclusion

GHK-Cu Reconstitution Protocol:

Special Considerations Copper-Peptide:

• GHK-Cu has unique properties due to its metal complex.
• Normal blue-purple color (indicates intact Cu²⁺ chelation)
• Sensitive to extreme pH (8.5)
• Potential oxidation in the presence of prolonged oxygen

Step-by-Step Procedure:

1. Initial Preparation:
   • Balance lyophilized vial room temperature 15 minutes
   • Clean the cap with isopropyl alcohol 70%
   • Prepare sterile environment
2. Diluent Selection
   • Optimal Sterile bacteriostatic water (pH 6.5-7.5)
   • Alternative 0.9% saline solution, pH adjusted
   • Avoid Solutions with EDTA or chelating agents (compete with Cu²⁺)
   • Temperature: room temperature
3. Recommended Concentrations:
   • Vial 50mg: Add 25mL → 2mg/mL (stock solution)
   • For topical use: dilute to 0.5–2% in an appropriate vehicle
   • For injection: maintain 1-2mg/mL
   • For in vitro studies: prepare 10mM stocks in DMSO or water
4. Reconstitution Technique
   • Slowly inject through the vial wall (45-60 seconds)
   • Stir gently until completely dissolved (2-5 minutes)
   • The solution should be light blue/purple and transparent.
   • Do not shake vigorously (potential denaturation)
5. Quality Check:
   • Color: characteristic blue-purple
   • Clarity: transparent without sediment
   • pH: check 6.5-7.5 if critical
   • Discard if green/brown (degradation/oxidation)

Post-Reconstitution Storage:

Oxidation Protection

• Minimize air exposure (use small vials)
• Flush nitrogen for long-term storage
• Add mild antioxidants (ascorbic acid 0.1%) if appropriate
• Fresh reconstitution preferred for critical studies

P: GHK-Cu vs. free GHK (copper-free)? Copper is essential for full activity:

• GHK-Cu Superior antioxidant activity (200%), better anti-inflammatory effect
• GHK Free Lower power (30-40% vs. Cu complex), unstable
• Optimal ratio: 1:1 GHK:Cu²⁺ (complete chelation)
• Studies show that the effects of 75-80% depend on the presence of copper

What is the optimal concentration for topical applications? R: It depends on the objective:

• Anti-aging 0.5–11 TP3T in serum/cream (clinical studies)
• Wound healing 1-2% gel/ointment
• Hair growth 0.5–11 TP3T in topical solution
• Concentrations >3% with no additional benefit; possible irritation

Stability in cosmetic formulations? Formulation Considerations:

• Optimal pH: 6.5-7.5 (out of range: complex dissociation)
• Incompatibilities: EDTA, strong acids, strong bases
• Condoms: paraben-free, phenoxyethanol-free
• Antioxidants: Vitamin E, ferulic acid improve stability
• Packaging: airless pumps, amber vials (light/oxygen sensitive)

Synergistic combinations for skin regeneration? R: Validated Combinations:

• GHK-Cu + Vitamin C: Collagen Synthesis Synergy (+40% vs. monotherapy)
• GHK-Cu + Retinoids Complementary, reduce irritation retinoids
• GHK-Cu + Hyaluronic Acid: Hydration + regeneration
• GHK-Cu + Signaling Peptides Matrixyl, Argireline (additive effects)

Safety of systemic copper in prolonged studies? Wide safety margin

• Typical GHK-Cu dosage: 1-5 mg/kg (0.3-1.5 mg Cu²⁺/kg)
• Toxic dose of Cu²⁺: >100 mg/kg (>50x therapeutic)
• Homeostasis covers: efficient liver regulation
• Monitor: ceruloplasmin, serum copper if >12 weeks treatment
• No accumulation in rodent studies for 6 months (2 mg/kg)

1. Pickart L, Margolina A. (2018) “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data” – Int J Mol Sci 19(7):1987. [PubMed: 29966389]
2. Pickart L, et al. (2012) “The human tri-peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health” – Oxidation and Cellular Longevity 2012:324832. [PubMed: 22685618]
3. Choi HR, et al. (2012) “Gly-His-Lys-Cu enhances wound healing and skin regeneration by upregulating expressions of VEGF and FGF2” – Archives of Dermatological Research 304(2):151-159. [PubMed: 22072067]
4. Pyo SJ, et al. (2022) “GHK-Cu promotes collagen synthesis and extends human fibroblast lifespan via telomerase activation” – J Dermatol Sci 106(2):89-97. [PubMed: 35340156]

1. Hong Y, et al. (2015) “GHK-Cu accelerates cutaneous wound healing via activation of TGF-β1 and Smad2/3 signaling” – Wound Repair Regen 23(1):65-73. [PubMed: 25403381]
2. Miller DM, et al. (1990) “Copper binding to the N-terminal amino group and the first peptide bond of glycyl peptides” – J Inorg Biochem 38(3):165-180. [PubMed: 2324530]
3. Arul V, et al. (2005) “Glycyl-histidyl-lysine (GHK) stimulates the proliferation of human dermal fibroblasts and promotes wound contraction” – Wound Repair Regen 13(1):63-72. [PubMed: 15659037]
4. Canapp SO, et al. (2016) “Topical GHK-Cu accelerates wound healing in dogs” – Journal of the American Animal Hospital Association52(5):278-285. [PubMed: 27487382]
5. Ahmed MR, et al. (2016) “GHK-Cu reduces neuroinflammation and improves cognitive function in Alzheimer's model” Neurobiology of Aging 46:44-55. [PubMed: 27460148]
6. Pollard JD, et al. (1973) “Human plasma copper glycylhistidyllysine and other small peptides” – Biochem J131(2):399-405. [PubMed: 4737293]

This browser does not support iframes. You can download the PDF here:
Download PDF.

This browser does not support iframes. You can download the PDF here:
Download PDF.